StockNews.com Initiates Coverage on Acorda Therapeutics (NASDAQ:ACOR)

Research analysts at StockNews.com assumed coverage on shares of Acorda Therapeutics (NASDAQ:ACOR – Get Rating) in a research report issued to clients and investors on Wednesday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Acorda Therapeutics stock opened at $0.56 on Wednesday. The stock has a market cap of $7.49 million, a P/E ratio of -0.07 and a beta of 0.49. The company has a debt-to-equity ratio of 1.43, a current ratio of 1.75 and a quick ratio of 1.43. Acorda Therapeutics has a 1 year low of $0.28 and a 1 year high of $6.36. The firm’s 50 day moving average price is $0.78 and its 200-day moving average price is $1.60.

An institutional investor recently raised its position in Acorda Therapeutics stock. Acadian Asset Management LLC lifted its holdings in Acorda Therapeutics, Inc. (NASDAQ:ACOR – Get Rating) by 22.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 467,739 shares of the biopharmaceutical company’s stock after purchasing an additional 85,335 shares during the quarter. Acadian Asset Management LLC owned 4.18% of Acorda Therapeutics worth $1,116,000 at the end of the most recent quarter. Institutional investors and hedge funds own 29.95% of the company’s stock.

Acorda Therapeutics Company Profile (Get Rating)

Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe.

Featured Stories